Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial

Complete Title: APEC1621M: NCI-COG PEDIATRIC MATCH (MOLECULAR ANALYSIS FOR THERAPY CHOICE) - PHASE 2 SUBPROTOCOL OF TIPIFARNIB IN PATIENTS WITH TUMORS HARBORING HRAS GENOMIC ALTERATIONS

Trial Phase: II

Investigator: Katherine Tarlock

This phase II pediatric MATCH trial studies how well tipifarnib works in treating patients with solid tumors that have recurred or spread to other places in the body (advanced), lymphoma, or histiocytic disorders, that have a genetic alteration in the gene HRAS. Tipifarnib may block the growth of cancer cells that have specific genetic changes in a gene called HRAS and may reduce tumor size.

Keywords:

Glioma
Kidney Cancer
Medulloblastoma
Melanoma
Neuroblastoma
Lymphoma, Non-Hodgkin (NHL)
Sarcoma
Solid Tumors
Thyroid Cancer
Neoplasms, Germ Cell and Embryonal
Ependymoma
Rhabdomyosarcoma
Sarcoma, Ewing
Pheochromocytoma
Osteosarcoma
Sarcoma, Soft Tissue
Rhabdoid Tumor
Histiocytosis, Langerhans-Cell
Hepatoblastoma
Neuroectodermal Tumors, Primitive, Peripheral

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Join a Clinical Trial

Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each clinical trial.

Contact Us

If you are seeking to schedule an appointment, we are here to help. You can either call us or fill out our online appointment request form.